Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Semaglutide, the active ingredient in Ozempic and Wegovy, may do more than manage diabetes and weight — it could also protect your lungs. A large real-world study found semaglutide use was linked to nearly 40% fewer asthma attacks and 20% fewer COPD flare-ups. Researchers caution that clinical trials are still needed before it can be recommended specifically for respiratory conditions.
Ozempic's surprise benefit: Fewer asthma attacks and COPD flare-ups
Semaglutide — the active ingredient in Ozempic and Wegovy — may have a notable bonus perk: better lung health. A large real-world study presented at the European Respiratory Society Congress in Barcelona found that people with asthma or COPD who took semaglutide experienced significantly fewer respiratory attacks compared to those on other diabetes medications.
Researchers at Imperial College London analyzed electronic health records from the UK, running four parallel studies each involving 20,000–22,000 patients. Among all GLP-1 receptor agonists studied, semaglutide showed the strongest effect — particularly in asthma patients. Scientists believe the drug's anti-inflammatory properties may be contributing to the respiratory benefits.
By the Numbers
Why it matters: Asthma and COPD affect hundreds of millions globally, and many patients also live with obesity or type 2 diabetes — conditions already treated with GLP-1 drugs. If confirmed in clinical trials, semaglutide could offer a meaningful dual benefit, reshaping how metabolic and respiratory care are integrated. Experts stress that patients should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance.
